サンプルお申込み

お問い合わせ

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は慢性閉塞性肺疾患(COPD)市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは慢性閉塞性肺疾患(COPD)の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の慢性閉塞性肺疾患(COPD)市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは慢性閉塞性肺疾患(COPD)のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に慢性閉塞性肺疾患(COPD)市場を分類しています。本研究に含まれる主な企業は：GSK、Pfizer、Merck、Novartis、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceuticals、Ario Pharma、Roche、Ache、Almirall、Aquinox Pharmaceuticals、Asmacure、Astellas Pharma

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Short-Acting Bronchodilators
    Corticosteroids
    Methylxanthines
    Long-Acting Bronchodilators
    Phosphodiesterase-4 Inhibitors
    Others

用途別の市場セグメント：
    Hospital
    Clinic

本レポートの詳細内容
世界の慢性閉塞性肺疾患(COPD)市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、慢性閉塞性肺疾患(COPD)タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の慢性閉塞性肺疾患(COPD)収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の慢性閉塞性肺疾患(COPD)市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、慢性閉塞性肺疾患(COPD)市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

慢性閉塞性肺疾患(COPD)のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：慢性閉塞性肺疾患(COPD)のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：慢性閉塞性肺疾患(COPD)の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章慢性閉塞性肺疾患(COPD)企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：慢性閉塞性肺疾患(COPD)の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：慢性閉塞性肺疾患(COPD)の主要企業の概要を提供し、製品の説明と仕様、慢性閉塞性肺疾患(COPD)の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disorder (COPD) Market
The global Chronic Obstructive Pulmonary Disorder (COPD) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition characterized by persistent airflow limitation that makes it difficult to breathe. COPD encompasses a group of diseases, with the most common being emphysema and chronic bronchitis. 
Emphysema involves the destruction of the air sacs in the lungs, while chronic bronchitis is marked by inflammation and narrowing of the airways. Symptoms include shortness of breath, chronic cough, excessive mucus production, wheezing, and tightness in the chest. COPD is often caused by long-term exposure to irritants, such as cigarette smoke, air pollution, and occupational dust or chemicals.
The condition is progressive and can significantly impact an individual's quality of life. In advanced stages, COPD can result in severe respiratory complications and exacerbations, potentially leading to hospitalizations.
Treatment for COPD typically involves a combination of medication, pulmonary rehabilitation, oxygen therapy, and in severe cases, surgical intervention such as lung volume reduction surgery or lung transplantation. Quitting smoking, avoiding lung irritants, and getting vaccinations to prevent respiratory infections are also essential components of COPD management.
COPD is a major public health concern globally, as it can cause significant morbidity and mortality. Early diagnosis, proper management, and lifestyle modifications are critical for maintaining the respiratory function and improving the well-being of individuals living with COPD.
Report Covers:
This report presents an overview of global market for Chronic Obstructive Pulmonary Disorder (COPD) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Chronic Obstructive Pulmonary Disorder (COPD), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Chronic Obstructive Pulmonary Disorder (COPD), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chronic Obstructive Pulmonary Disorder (COPD) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Chronic Obstructive Pulmonary Disorder (COPD) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Chronic Obstructive Pulmonary Disorder (COPD) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma and Roche, etc.

Market Segmentation
By Company
    GSK
    Pfizer
    Merck
    Novartis
    AstraZeneca
    Boehringer Ingelheim
    Teva Pharmaceuticals
    Ario Pharma
    Roche
    Ache
    Almirall
    Aquinox Pharmaceuticals
    Asmacure
    Astellas Pharma

Segment by Type
    Short-Acting Bronchodilators
    Corticosteroids
    Methylxanthines
    Long-Acting Bronchodilators
    Phosphodiesterase-4 Inhibitors
    Others

Segment by Application
    Hospital
    Clinic

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Chronic Obstructive Pulmonary Disorder (COPD) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chronic Obstructive Pulmonary Disorder (COPD) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Short-Acting Bronchodilators
    Table 3. Key Players of Corticosteroids
    Table 4. Key Players of Methylxanthines
    Table 5. Key Players of Long-Acting Bronchodilators
    Table 6. Key Players of Phosphodiesterase-4 Inhibitors
    Table 7. Key Players of Others
    Table 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2019-2024) & (US$ Million)
    Table 11. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2019-2024)
    Table 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2025-2030)
    Table 14. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends
    Table 15. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
    Table 16. Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
    Table 17. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
    Table 18. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Players (2019-2024) & (US$ Million)
    Table 19. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Players (2019-2024)
    Table 20. Global Top Chronic Obstructive Pulmonary Disorder (COPD) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2023)
    Table 21. Global Chronic Obstructive Pulmonary Disorder (COPD) Industry Ranking 2022 VS 2023 VS 2024
    Table 22. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue (CR5 and HHI) & (2019-2024)
    Table 23. Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Headquarters and Area Served
    Table 24. Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Product and Application
    Table 25. Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Product and Application
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2019-2024) & (US$ Million)
    Table 28. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2019-2024)
    Table 29. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 30. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2025-2030)
    Table 31. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2019-2024) & (US$ Million)
    Table 32. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Application (2019-2024)
    Table 33. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 34. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Application (2025-2030)
    Table 35. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2019-2024) & (US$ Million)
    Table 36. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2025-2030) & (US$ Million)
    Table 37. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2019-2024) & (US$ Million)
    Table 38. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2025-2030) & (US$ Million)
    Table 39. North America Chronic Obstructive Pulmonary Disorder (COPD) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 40. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2019-2024) & (US$ Million)
    Table 41. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2025-2030) & (US$ Million)
    Table 42. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2019-2024) & (US$ Million)
    Table 43. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2025-2030) & (US$ Million)
    Table 44. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2019-2024) & (US$ Million)
    Table 45. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2025-2030) & (US$ Million)
    Table 46. Europe Chronic Obstructive Pulmonary Disorder (COPD) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 47. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2019-2024) & (US$ Million)
    Table 48. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2025-2030) & (US$ Million)
    Table 49. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2019-2024) & (US$ Million)
    Table 50. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2025-2030) & (US$ Million)
    Table 51. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2019-2024) & (US$ Million)
    Table 52. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2025-2030) & (US$ Million)
    Table 53. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2019-2024) & (US$ Million)
    Table 54. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2025-2030) & (US$ Million)
    Table 55. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2019-2024) & (US$ Million)
    Table 56. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2025-2030) & (US$ Million)
    Table 57. Asia Chronic Obstructive Pulmonary Disorder (COPD) Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 58. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2019-2024) & (US$ Million)
    Table 59. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2025-2030) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 65. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2019-2024) & (US$ Million)
    Table 66. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2025-2030) & (US$ Million)
    Table 67. GSK Company Details
    Table 68. GSK Business Overview
    Table 69. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 70. GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 71. GSK Recent Developments
    Table 72. Pfizer Company Details
    Table 73. Pfizer Business Overview
    Table 74. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 75. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 76. Pfizer Recent Developments
    Table 77. Merck Company Details
    Table 78. Merck Business Overview
    Table 79. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 80. Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 81. Merck Recent Developments
    Table 82. Novartis Company Details
    Table 83. Novartis Business Overview
    Table 84. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 85. Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 86. Novartis Recent Developments
    Table 87. AstraZeneca Company Details
    Table 88. AstraZeneca Business Overview
    Table 89. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 90. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 91. AstraZeneca Recent Developments
    Table 92. Boehringer Ingelheim Company Details
    Table 93. Boehringer Ingelheim Business Overview
    Table 94. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 95. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 96. Boehringer Ingelheim Recent Developments
    Table 97. Teva Pharmaceuticals Company Details
    Table 98. Teva Pharmaceuticals Business Overview
    Table 99. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 100. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 101. Teva Pharmaceuticals Recent Developments
    Table 102. Ario Pharma Company Details
    Table 103. Ario Pharma Business Overview
    Table 104. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 105. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 106. Ario Pharma Recent Developments
    Table 107. Roche Company Details
    Table 108. Roche Business Overview
    Table 109. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 110. Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 111. Roche Recent Developments
    Table 112. Ache Company Details
    Table 113. Ache Business Overview
    Table 114. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 115. Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 116. Ache Recent Developments
    Table 117. Almirall Company Details
    Table 118. Almirall Business Overview
    Table 119. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 120. Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 121. Almirall Recent Developments
    Table 122. Aquinox Pharmaceuticals Company Details
    Table 123. Aquinox Pharmaceuticals Business Overview
    Table 124. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 125. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 126. Aquinox Pharmaceuticals Recent Developments
    Table 127. Asmacure Company Details
    Table 128. Asmacure Business Overview
    Table 129. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 130. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 131. Asmacure Recent Developments
    Table 132. Astellas Pharma Company Details
    Table 133. Astellas Pharma Business Overview
    Table 134. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product
    Table 135. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024) & (US$ Million)
    Table 136. Astellas Pharma Recent Developments
    Table 137. Research Programs/Design for This Report
    Table 138. Key Data Information from Secondary Sources
    Table 139. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type: 2023 VS 2030
    Figure 3. Short-Acting Bronchodilators Features
    Figure 4. Corticosteroids Features
    Figure 5. Methylxanthines Features
    Figure 6. Long-Acting Bronchodilators Features
    Figure 7. Phosphodiesterase-4 Inhibitors Features
    Figure 8. Others Features
    Figure 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2023 VS 2030
    Figure 11. Hospital Case Studies
    Figure 12. Clinic Case Studies
    Figure 13. Chronic Obstructive Pulmonary Disorder (COPD) Report Years Considered
    Figure 14. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region: 2023 VS 2030
    Figure 17. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players in 2023
    Figure 18. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2023
    Figure 20. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type (2019-2030)
    Figure 22. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application (2019-2030)
    Figure 23. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2019-2030)
    Figure 24. United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 27. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type (2019-2030)
    Figure 28. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application (2019-2030)
    Figure 29. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2019-2030)
    Figure 30. Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. France Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. U.K. Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Nordic Countries Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. China Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type (2019-2030)
    Figure 38. China Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application (2019-2030)
    Figure 39. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 40. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type (2019-2030)
    Figure 41. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application (2019-2030)
    Figure 42. Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2019-2030)
    Figure 43. Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. China Taiwan Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. India Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY (2019-2030) & (US$ Million)
    Figure 50. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application (2019-2030)
    Figure 52. Middle East, Africa, and Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2019-2030)
    Figure 53. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Israel Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. GCC Countries Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 60. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 61. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 62. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 63. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 64. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 66. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 67. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 68. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 69. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 70. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 71. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 72. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2019-2024)
    Figure 73. Bottom-up and Top-down Approaches for This Report
    Figure 74. Data Triangulation
    Figure 75. Key Executives Interviewed